{"title": "PDF", "author": "PDF", "url": "https://europepmc.org/articles/PMC1968816/pdf/brjcancer00194-0143.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Sapporo, Japan;'TheSecondDepartment of patients 20(7%) 14(5%)34(6%) Non-invasive cancer 6 5 11 TIS I 0 1 Bilateral breastcancer 1 0 1 Concomitant malignancy 1 0 1 Inappropriate stages 7 8 15 Over76yearsofage 2 0 2 Previous cancertreatment 2 1 3 No.ofeligiblepatients 254 258 512 No.oftotalpatients 274 272 546 TableIIBackground factorsofeligiblepatients A B (n=254) (n=258) X2-test Age Median 48 49 Range 28-75 26-75 Menopausal status Pre 133 142 P=0.60 Post 121 116 Operation Modified 31 38 P=0.17 Standard 190 199 Extend 33 21 Nodalstatus 0 109 140 P=0.083 1-3 80 67 >4 65 51 Histology Invasive 245 243 P=0.45 Specialtypes 9 14 Unknown 0 1 ERstatus Positive 116 120 P=0.40 Negative 75 86 Unknown 63 52 TableIHFiveyearoverallsurvival ADOX+FT (256) 2 3 4 5 Yearsaftersurgery Figure2Overall survival.Stage(II,Ilia)-b I v a I ITAMOXIFEN Softtissues 17 Contralateral breast 2 4 Skin 9 4 Subcutis 16 6 Lymphnodes 24 7 Mediastinum and/orhilar 1 2 Miscellaneous 1 0 Bone 31 25 Viscera 20 20 Lung 10 12 Pleura 6 5 Pericardial fluid 1 0 Liver 7 5 Peritoneum 1 1 Brain 1 0 Miscellaneous I I Miscellaneous 1 1 No.ofpatientswithrecurrence 76 48 "}